Rejuran is a Korean-origin polynucleotide (PN) injectable that stimulates collagen and improves skin quality—but US availability remains limited despite growing practitioner and patient demand.
Rejuran is a polynucleotide (PN) skin booster—specifically a polydeoxyribonucleotide (PDRN) derived from salmon DNA—injected intradermally to stimulate fibroblast activity, boost collagen production, and improve skin texture, hydration, and radiance. Unlike dermal fillers that add volume, Rejuran works as a biostimulator, triggering the skin's own regenerative machinery over 4–12 weeks post-treatment.
The product originated in South Korea and has dominated the Asian aesthetic market for over a decade, particularly in Korea, Japan, and Southeast Asia. It is manufactured by Dalim Biotech and marketed under the Rejuran brand (Rejuran Healer, Rejuran S, and Rejuran Eye). The mechanism centers on PDRN's ability to bind to adenosine receptors on fibroblasts, activating the A2A receptor pathway and upregulating hyaluronic acid synthesis, collagen I and III deposition, and anti-inflammatory cytokine expression.
How Rejuran Works: The Mechanism
PDRN is a naturally occurring nucleotide chain extracted and purified from salmon sperm. When injected into the dermis at 1–2 mm depth, it does not integrate into human DNA; rather, it acts as a signaling molecule. The polynucleotide backbone stimulates fibroblasts to increase their own HA production and collagen remodeling, while simultaneously dampening pro-inflammatory markers like IL-6 and TNF-α. This dual action—regeneration plus anti-inflammation—differentiates PN boosters from hyaluronic acid fillers (which hydrate but do not stimulate) and from PLLA (Sculptra) or CaHA (Radiesse), which work via granulomatous foreign-body response rather than direct nucleotide signaling.
Clinical studies in the Korean and Japanese literature document improvements in skin elasticity, hydration, fine lines, and overall luminosity, with results typically visible 2–4 weeks post-injection and peaking around 8–12 weeks. The effect is cumulative; most practitioners recommend a series of 3–4 sessions spaced 1–2 weeks apart, followed by maintenance injections every 6–12 months.
US Regulatory Status and Availability
Rejuran is not FDA-approved in the United States. It remains an unapproved biologic under FDA purview, meaning it cannot be legally imported, marketed, or administered in US clinical practice. The product has not undergone the 510(k) or PMA pathway required for aesthetic injectables in America.
Rejuran commands 30–40% of the Asian skin-booster market but remains FDA-unapproved in the US, creating a regulatory gap between global demand and legal domestic availability.
However, demand from US practitioners and patients is rising. Some US practices source Rejuran through international channels (often from Korea or Singapore) and administer it off-label, a legally gray practice that exposes the provider to liability and regulatory risk. The FDA has not aggressively enforced against individual PN use, but importation and distribution remain technically prohibited. A handful of US-based companies have announced intentions to pursue FDA approval for polynucleotide products, but as of now, no PN booster has cleared the US market through official channels.
Why the Demand Gap Exists
In Asia, Rejuran commands 30–40% of the skin-booster market, competing with other PNs (Neauvia Hydro, Profhilo in some regions) and increasingly with biostimulators like PLLA and CaHA. US practitioners and patients are aware of Rejuran's efficacy and popularity abroad, driving interest. The mechanism is distinct from hyaluronic acid fillers and appeals to patients seeking collagen stimulation without volume addition—a gap in the current US aesthetic armamentarium between HA fillers and PLLA/CaHA.
The regulatory barrier is not scientific but bureaucratic: Rejuran would require clinical trial data, manufacturing compliance documentation, and FDA submission—an investment Dalim Biotech has not prioritized for the US market, likely due to the smaller addressable market and the dominance of Allergan Aesthetics and Galderma in the US injectables space.
Current Practitioner Landscape
US medspa and dermatology practices aware of Rejuran face a choice: wait for potential FDA approval, use off-label imported product (with attendant legal and supply-chain risk), or pivot to FDA-cleared alternatives like Sculptra (PLLA) or Radiesse (CaHA) for collagen-stimulation outcomes. Some practices have begun exploring other PN products that may have clearer regulatory pathways or are in clinical trials for US approval.
The polynucleotide category is likely to expand in the US market within the next 2–3 years as manufacturers recognize the gap and pursue approvals. Until then, Rejuran remains a high-demand, low-availability product—a classic case of global aesthetic innovation outpacing US regulatory clearance.
Frequently asked questions
Is Rejuran FDA approved in the United States?
No, Rejuran is not FDA-approved and remains an unapproved biologic in the US. It has not undergone the 510(k) or PMA pathway required for aesthetic injectables, meaning it cannot be legally imported, marketed, or administered in clinical practice.
How long does it take to see results from Rejuran injections?
Results typically become visible 2–4 weeks post-injection and peak around 8–12 weeks. Most practitioners recommend a series of 3–4 sessions spaced 1–2 weeks apart to maximize the cumulative effect, followed by maintenance injections every 6–12 months.
What is the difference between Rejuran and dermal fillers like Juvederm?
Rejuran is a biostimulator that triggers the skin's own collagen production and hyaluronic acid synthesis, whereas dermal fillers add volume directly. Rejuran works through nucleotide signaling to fibroblasts rather than providing immediate volumization, making it ideal for patients seeking skin quality improvement without added volume.
How does Rejuran compare to Sculptra or Radiesse?
While Sculptra (PLLA) and Radiesse (CaHA) are FDA-approved biostimulators, they work via granulomatous foreign-body response. Rejuran uses direct nucleotide signaling through the A2A receptor pathway to stimulate fibroblasts, collagen deposition, and hyaluronic acid synthesis, plus anti-inflammatory effects that differentiate its mechanism.
What market share does Rejuran hold in Asia?
Rejuran commands 30–40% of the skin-booster market in Asia, particularly dominating Korea, Japan, and Southeast Asia for over a decade. It competes with other polynucleotides and biostimulators like PLLA and CaHA in those regions.
Can US practitioners legally use Rejuran?
No. While some US practices source Rejuran through international channels and administer it off-label, this is a legally gray practice that exposes providers to liability and regulatory risk. Importation and distribution remain technically prohibited by the FDA, though enforcement against individual use has not been aggressive to date.
Free weekly brief Get the free weekly brief.
The week's most important moves in medical aesthetics — distilled to a two-minute read, free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief every morning. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
